182 related articles for article (PubMed ID: 16009045)
1. Genetic modification of hematopoietic cells using retroviral and lentiviral vectors: safety considerations for vector design and delivery into target cells.
Dropulic B
Curr Hematol Rep; 2005 Jul; 4(4):300-4. PubMed ID: 16009045
[TBL] [Abstract][Full Text] [Related]
2. A roadmap to safe, efficient, and stable lentivirus-mediated gene therapy with hematopoietic cell transplantation.
Neschadim A; McCart JA; Keating A; Medin JA
Biol Blood Marrow Transplant; 2007 Dec; 13(12):1407-16. PubMed ID: 18022569
[TBL] [Abstract][Full Text] [Related]
3. The leukemogenic risk of integrating retroviral vectors in hematopoietic stem cell gene therapy applications.
Kang EM; Tisdale JF
Curr Hematol Rep; 2004 Jul; 3(4):274-81. PubMed ID: 15217557
[TBL] [Abstract][Full Text] [Related]
4. Is it going to be SIN?: a European Society of Gene Therapy commentary. Phasing-out the clinical use of non self-inactivating murine leukemia virus vectors: initiative on hold.
Buchholz CJ; Cichutek K
J Gene Med; 2006 Oct; 8(10):1274-6. PubMed ID: 17001625
[TBL] [Abstract][Full Text] [Related]
5. Retroviral vectors for gene therapy of AIDS and cancer.
Chang LJ; He J
Curr Opin Mol Ther; 2001 Oct; 3(5):468-75. PubMed ID: 11699891
[TBL] [Abstract][Full Text] [Related]
6. Murine leukemia following irradiation conditioning for transplantation of lentivirally-modified hematopoietic stem cells.
Siapati EK; Bigger BW; Kashofer K; Themis M; Thrasher AJ; Bonnet D
Eur J Haematol; 2007 Apr; 78(4):303-13. PubMed ID: 17378892
[TBL] [Abstract][Full Text] [Related]
7. Genotoxicity of retroviral integration in hematopoietic cells.
Nienhuis AW; Dunbar CE; Sorrentino BP
Mol Ther; 2006 Jun; 13(6):1031-49. PubMed ID: 16624621
[TBL] [Abstract][Full Text] [Related]
8. Shuttle of lentiviral vectors via transplanted cells in vivo.
Blömer U; Gruh I; Witschel H; Haverich A; Martin U
Gene Ther; 2005 Jan; 12(1):67-74. PubMed ID: 15385952
[TBL] [Abstract][Full Text] [Related]
9. Current development of lentiviral-mediated gene transfer.
Romano G
Drug News Perspect; 2005 Mar; 18(2):128-34. PubMed ID: 15883621
[TBL] [Abstract][Full Text] [Related]
10. Fragile sites are preferential targets for integrations of MLV vectors in gene therapy.
Bester AC; Schwartz M; Schmidt M; Garrigue A; Hacein-Bey-Abina S; Cavazzana-Calvo M; Ben-Porat N; Von Kalle C; Fischer A; Kerem B
Gene Ther; 2006 Jul; 13(13):1057-9. PubMed ID: 16511518
[TBL] [Abstract][Full Text] [Related]
11. Lentiviral vectors pseudotyped with murine ecotropic envelope: increased biosafety and convenience in preclinical research.
Schambach A; Galla M; Modlich U; Will E; Chandra S; Reeves L; Colbert M; Williams DA; von Kalle C; Baum C
Exp Hematol; 2006 May; 34(5):588-92. PubMed ID: 16647564
[TBL] [Abstract][Full Text] [Related]
12. Efficiency of transduction of highly purified murine hematopoietic stem cells by lentiviral and oncoretroviral vectors under conditions of minimal in vitro manipulation.
Mostoslavsky G; Kotton DN; Fabian AJ; Gray JT; Lee JS; Mulligan RC
Mol Ther; 2005 Jun; 11(6):932-40. PubMed ID: 15922964
[TBL] [Abstract][Full Text] [Related]
13. Progress toward the genetic treatment of the beta-thalassemias.
Sadelain M; Lisowski L; Samakoglu S; Rivella S; May C; Riviere I
Ann N Y Acad Sci; 2005; 1054():78-91. PubMed ID: 16339654
[TBL] [Abstract][Full Text] [Related]
14. Onco-retroviral and lentiviral vector-based gene therapy for hemophilia: preclinical studies.
Van Damme A; Chuah MK; Collen D; VandenDriessche T
Semin Thromb Hemost; 2004 Apr; 30(2):185-95. PubMed ID: 15118930
[TBL] [Abstract][Full Text] [Related]
15. Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors--design, biosafety, and production.
Sinn PL; Sauter SL; McCray PB
Gene Ther; 2005 Jul; 12(14):1089-98. PubMed ID: 16003340
[TBL] [Abstract][Full Text] [Related]
16. Equal potency of gammaretroviral and lentiviral SIN vectors for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells.
Schambach A; Bohne J; Chandra S; Will E; Margison GP; Williams DA; Baum C
Mol Ther; 2006 Feb; 13(2):391-400. PubMed ID: 16226060
[TBL] [Abstract][Full Text] [Related]
17. Efficient lentiviral transduction of Herpesvirus saimiri immortalized T cells as a model for gene therapy in primary immunodeficiencies.
Toscano MG; Frecha C; Ortega C; Santamaría M; Martín F; Molina IJ
Gene Ther; 2004 Jun; 11(12):956-61. PubMed ID: 15029233
[TBL] [Abstract][Full Text] [Related]
18. Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy.
Vigna E; Naldini L
J Gene Med; 2000; 2(5):308-16. PubMed ID: 11045424
[TBL] [Abstract][Full Text] [Related]
19. [Gene therapy of severe combined immunodeficiency disease: proof of principle of efficiency and safety issues. Gene therapy, primary immunodeficiencies, retrovirus, lentivirus, genome].
Fischer A; Hacein-Bey-Abina S; Lagresle C; Garrigue A; Cavazana-Calvo M
Bull Acad Natl Med; 2005 May; 189(5):779-85; discussion 786-8. PubMed ID: 16433450
[TBL] [Abstract][Full Text] [Related]
20. Oncogenesis following delivery of a nonprimate lentiviral gene therapy vector to fetal and neonatal mice.
Themis M; Waddington SN; Schmidt M; von Kalle C; Wang Y; Al-Allaf F; Gregory LG; Nivsarkar M; Themis M; Holder MV; Buckley SM; Dighe N; Ruthe AT; Mistry A; Bigger B; Rahim A; Nguyen TH; Trono D; Thrasher AJ; Coutelle C
Mol Ther; 2005 Oct; 12(4):763-71. PubMed ID: 16084128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
